Gene drives

The first contained self-spreading trial has no near-term path after Burkina Faso

Target Malaria – the only consortium close to a first contained self-spreading gene-drive trial – was suspended across Burkina Faso in August 2025 after a routine non-drive release: the Bobo-Dioulasso insectary was sealed and the modified strains destroyed, and the linked Uganda and Ghana programmes stalled with it. No self-spreading drive now sits on any near-term regulatory pathway under any national framework. The watch-item is whether the consortium re-establishes a host-country agreement elsewhere in West or East Africa; until then the precedent-setting first field trial that the whole category depends on is indefinitely deferred, and funding logic compresses toward containment research and self-limiting alternatives.

A procedural regulatory pathway exists, but it does not endorse release

WHO GMM guidance and the UN Convention on Biological Diversity (Cali COP-16, 2024) establish a case-by-case national approval pathway with biosafety review and community consultation. This removes the old no-pathway obstacle, but the framework deliberately stops short of endorsing self-spreading release, and the Burkina Faso suspension showed national authorities can halt even a compliant non-drive release on sovereignty and consent grounds. The next test is CBD COP-17 and Cartagena CP-MOP-12 (Yerevan, October 2026): a tightening of the gene-drive risk-assessment track would push the category further toward self-limiting approaches only.

Oxitec self-limiting Aedes aegypti is the proven commercial path

Self-limiting (not self-spreading) gene-modified mosquitoes are the only genetically engineered vector-control approach with a live commercial pathway. Oxitec holds full Brazilian CTNBio commercial approval for its Friendly Aedes aegypti and distributes nationally through 20-plus partners. Self-limiting designs cannot persist or spread in the wild, sidestepping the ecological-irreversibility objections that dog self-spreading drives. The open question is the US: the EPA experimental-use permit lapsed in April 2024 and full Section 3 registration is still pending, so US commercial scale-up cannot proceed until the EPA registers the product.

State of the art (2026)

The field has gone backwards. In August 2025 Burkina Faso suspended Target Malaria, sealed its insectary and ordered destruction of the modified strains after a release of 16,000 sterile (non-drive) males - halting the consortium's only credible route to a first contained gene-drive trial and chilling the linked Uganda and Ghana programmes. No self-spreading drive sits on any near-term regulatory pathway. The proven path remains self-limiting, non-drive biocontrol: Oxitec holds Brazilian CTNBio commercial approval but its US releases lapsed in 2024 and it still awaits full EPA registration. CBD COP-17 and Cartagena CP-MOP-12 (Yerevan, October 2026) will set the governance tone. Funding stays philanthropic and public - Gates, Wellcome, DARPA Safe Genes - with no venture-scale commercial case.